2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-U00063
    Tiopinac 61220-69-7 ≥99.0%
    Tiopinac (RS 40974), a dibenzthiepin, is an orally active and highly potent anti-inflammatory and anti-pyretic agent.
    Tiopinac
  • HY-U00307
    Carabersat 184653-84-7 98.22%
    Carabersat is a potent anticonvulsant agent.
    Carabersat
  • HY-U00373
    Revexepride 219984-49-3 99.84%
    Revexepride is a highly selective 5-HT4 receptor agonist, and a potential inducer of CYP3A4 enzyme, used for the treatment of gastroesophageal reflux disease.
    Revexepride
  • HY-U00382
    Substance P Receptor Antagonist 1 225526-17-0 99.42%
    Substance P Receptor Antagonist 1 has the potential function in central nervous system disorders, respiratory, inflammatory diseases and gastrointestinal disorders.
    Substance P Receptor Antagonist 1
  • HY-U00427
    PDE2/PDE10-IN-1 1426833-08-0 ≥98.0%
    PDE2/PDE10-IN-1 is a phosphodiesterase 2 (PDE2) and PDE10 inhibitor with IC50s of 29 and 480 nM, respectively.
    PDE2/PDE10-IN-1
  • HY-Y0258R
    Benzocaine (Standard) 94-09-7 99.99%
    Benzocaine (Standard) is the analytical standard of Benzocaine. This product is intended for research and analytical applications. Benzocaine shares a common receptor with all othe rLAs in the voltage-gated Na+ channel, with an IC50 of 0.8 mM tested with a potential of +30 mV.
    Benzocaine (Standard)
  • HY-100027A
    Ro 41-1049 hydrochloride 127917-66-2 99.96%
    Ro 41-1049 hydrochloride is a reversible and selective inhibitor of monoamine oxidase-A (MAO-A). An homogeneous population of high affinity binding sites for [3H]Ro 41-1049 is found in membrane preparations from human frontal cortex and placenta (Kd values of 16.5 and 64.4 nM, respectively).
    Ro 41-1049 hydrochloride
  • HY-100588A
    VU0364770 hydrochloride 1414842-70-8 99.70%
    VU0364770 hydrochloride is a selective and potent positive allosteric modulator (PAM) of mGlu4. VU0346770 hydrochloride exhibits EC50s of 290 nM and 1.1 μM at rat mGlu4 and human mGlu4 receptor, respectively. VU0364770 hydrochloride exhibits antagonist activity at mGlu5 with a potency of 17.9 μM and PAM activity at mGlu6 with a potency of 6.8 μM. VU0364770 hydrochloride also possesses activity at MAO with Ki values of 8.5 and 0.72 μM for human MAO-A and human MAO-B, respectively.
    VU0364770 hydrochloride
  • HY-100781B
    L-AP4 monohydrate 2247534-79-6 ≥99.0%
    L-AP4 (L-APB) monohydrate is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively.
    L-AP4 monohydrate
  • HY-100805R
    D-Glutamic acid (Standard) 6893-26-1
    D-Glutamic acid (Standard) is the analytical standard of D-Glutamic acid. This product is intended for research and analytical applications. D-glutamic acid, an enantiomer of L- glutamic acid, is widely used in pharmaceuticals and foods.
    D-Glutamic acid (Standard)
  • HY-100822A
    (S)-(-)-HA 966 111821-58-0 ≥98.0%
    (S)-(-)-HA 966 ((-)-HA 966), a γ-Hydroxybutyrate-like agent, is weakly active as an NMDA-receptor antagonist. (S)-(-)-HA 966 possesses muscle relaxant action and prevents enhanced mesocorticolimbic dopamine metabolism and behavioral correlates of restraint stress, conditioned fear.
    (S)-(-)-HA 966
  • HY-101036R
    Choline bitartrate (Standard) 87-67-2
    Choline (bitartrate) (Standard) is the analytical standard of Choline (bitartrate). This product is intended for research and analytical applications. Choline bitartrate is a vitamin-like essential nutrient, can affect diseases such as liver disease, atherosclerosis and neurological disorders. Choline bitartrate is a precursor for the neurotransmitter acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.
    Choline bitartrate (Standard)
  • HY-101541S
    Docosahexaenoic acid-d5 methyl ester 2687960-96-7 98%
    Docosahexaenoic acid-d5 methyl ester is the deuterium labeled Docosahexaenoic Acid methyl ester. Docosahexaenoic Acid methyl ester is a methylated docosahexaenoic acid analog which can be intercalated into membrane phospholipids without being oxidized or hydrolyzed.
    Docosahexaenoic acid-d5 methyl ester
  • HY-101639A
    CP-409092 hydrochloride 225240-86-8 99.79%
    CP-409092 hydrochloride is a partial agonist of GABAA receptor, with anti-anxiety activity.
    CP-409092 hydrochloride
  • HY-101939A
    RP-001 hydrochloride 1781880-34-9 98.8%
    RP-001 hydrochloride is a picomolar short-acting S1P1 (EDG1) selective agonist, with an EC50 of 9 pM. RP-00 hydrochloride induces internalization and polyubiquitination of S1P1. RP-001 hydrochloride has little activity on S1P2-S1P4 and only moderate affinity for S1P5.
    RP-001 hydrochloride
  • HY-102091A
    (2R,4R)-APDC hydrate ≥98.0%
    (2R,4R)-APDC hydrate ((2R,4R)-4-Aminopyrrolidine-2,4-dicarboxylic acid hydrate) is a group II metabotropic glutamate receptor (mGluR) agonist. (2R,4R)-APDC hydrate affects cell proliferation by inhibiting glutamate release, enhancing motor responses produced by D1 receptor activation, or reducing brain-derived neurotrophic factor (BDNF) levels. (2R,4R)-APDC hydrate can be used in the study of epilepsy and other neurological diseases.
    (2R,4R)-APDC hydrate
  • HY-103105A
    LP 12 hydrochloride hydrate ≥99.0%
    LP 12 hydrochloride hydrate is a potent and selective 5-HT7 receptor agonist with a Ki of 0.13 nM. LP 12 hydrochloride hydrate displays selectivity for 5-HT7 over D2, 5-HT1A and 5-HT2A receptors (Ki values are 224 nM, 60.9 nM and >1000 nM, respectively).
    LP 12 hydrochloride hydrate
  • HY-103112A
    SB 243213 dihydrochloride 1780372-25-9 ≥99.0%
    SB 243213 dihydrochloride is an orally active, selective and high-affinity 5-HT2C receptor antagonist with a pKi of 9.37 and a pKb of 9.8 for human 5-HT2C receptor. SB 243213 dihydrochloride shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels. SB 243213 dihydrochloride has improved anxiolytic profile and has the potential for schizophrenia and motor disorders.
    SB 243213 dihydrochloride
  • HY-103668A
    SSD114 hydrochloride 2319790-02-6 99.13%
    SSD114 hydrochloride is a novel GABAB receptor positive allosteric modulator.
    SSD114 hydrochloride
  • HY-105084A
    Lubeluzole dihydrochloride 144665-09-8 99.00%
    Lubeluzole (dihydrochloride) is a neuroprotective agent which blockades neuronal voltage-gated sodium channels. Lubeluzole (dihydrochloride) also produces both tonic and block of cardiac sodium channels. Lubeluzole (dihydrochloride) is promising for research of antiarrhythmic agents.
    Lubeluzole dihydrochloride
Cat. No. Product Name / Synonyms Application Reactivity